Literature DB >> 21499972

Carriage and invasive isolates of Streptococcus pneumoniae in Caracas, Venezuela: the relative invasiveness of serotypes and vaccine coverage.

I A Rivera-Olivero1, B del Nogal, M C Sisco, D Bogaert, P W M Hermans, J H de Waard.   

Abstract

The introduction of a pneumococcal conjugate vaccine in Venezuela needs previous studies to assess vaccine efficiency. We conducted a survey of nasopharyngeal pneumococcal carriage in urban children in Caracas and studied the distribution of serotypes. We compared these data with survey data available for invasive strains isolated in the same area and in the same time period. An overall pneumococcal carriage rate of 27% was observed. The most predominant capsular serotypes among carriage isolates were 6B (29%), 19A (13.8%), 23F (10%), 14 (8.3%), 6A (8.3%) and 15B/C (3.3%) and among invasive isolates 6B (25%), 14 (15%), and 19A, 6A, 7F, and 18 (7.5% each). The serotypes/groups 1, 5, 7F and 18, jointly covering 30% of the invasive strains, represented less than 0.7% of the carrier strains. The theoretical coverage of the pneumococcal conjugate vaccine PCV13 for carriage and invasive strains was calculated to be 74% and 90%, respectively. Our study demonstrates important differences for the serotype distribution in disease and carriage isolates and provides a key baseline for future studies addressing the prevalence and replacement of invasive and carriage serotypes after the introduction of the PCV 13 vaccine in Venezuela in the year 2010.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499972     DOI: 10.1007/s10096-011-1247-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  22 in total

1.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

2.  The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Authors:  W P Hausdorff; J Bryant; C Kloek; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

3.  [Prevalence of Streptococcus pneumoniae serotypes on nasopharyngeal colonization in children of Mexico City].

Authors:  Fortino Solórzano-Santos; Laura Alicia Ortiz-Ocampo; Ma Guadalupe Miranda-Novales; Gabriela Echániz-Avilés; Araceli Soto-Noguerón; Héctor Guiscafré-Gallardo
Journal:  Salud Publica Mex       Date:  2005 Jul-Aug

4.  Pneumococcal carriage in children in The Netherlands: a molecular epidemiological study.

Authors:  D Bogaert; M N Engelen; A J Timmers-Reker; K P Elzenaar; P G Peerbooms; R A Coutinho; R de Groot; P W Hermans
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

Review 5.  Epidemiological differences among pneumococcal serotypes.

Authors:  William P Hausdorff; Daniel R Feikin; Keith P Klugman
Journal:  Lancet Infect Dis       Date:  2005-02       Impact factor: 25.071

6.  Susceptibility of pneumococcal carriage isolates to penicillin provides a conservative estimate of susceptibility of invasive pneumococci.

Authors:  D Lehmann; M Gratten; J Montgomery
Journal:  Pediatr Infect Dis J       Date:  1997-03       Impact factor: 2.129

Review 7.  Streptococcus pneumoniae colonisation: the key to pneumococcal disease.

Authors:  D Bogaert; R De Groot; P W M Hermans
Journal:  Lancet Infect Dis       Date:  2004-03       Impact factor: 25.071

8.  Use of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in Pakistan for surveillance for antimicrobial resistance.

Authors:  T D Mastro; N K Nomani; Z Ishaq; A Ghafoor; N F Shaukat; E Esko; M Leinonen; J Henrichsen; R F Breiman; B Schwartz
Journal:  Pediatr Infect Dis J       Date:  1993-10       Impact factor: 2.129

9.  Serotypes of carriage and invasive isolates of Streptococcus pneumoniae in Brazilian children in the era of pneumococcal vaccines.

Authors:  C B Laval; A L S S de Andrade; F C Pimenta; J G de Andrade; R M de Oliveira; S A Silva; E C de Lima; J L Fabio; S T Casagrande; M C C Brandileone
Journal:  Clin Microbiol Infect       Date:  2006-01       Impact factor: 8.067

10.  Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life.

Authors:  B M Gray; G M Converse; H C Dillon
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

View more
  4 in total

1.  Estimation of the invasive disease potential of Streptococcus pneumoniae in children by the use of direct capsular typing in clinical specimens.

Authors:  E del Amo; L Selva; M F de Sevilla; P Ciruela; P Brotons; M Triviño; S Hernandez; J J Garcia-Garcia; Á Dominguez; C Muñoz-Almagro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-21       Impact factor: 3.267

2.  Nasopharyngeal carriage of Streptococcus pneumoniae among children in an urban setting in Brazil prior to PCV10 introduction.

Authors:  Ana Paula de O Menezes; Jailton Azevedo; Mariela C Leite; Leila C Campos; Marcelo Cunha; Maria da Gloria S Carvalho; Mitermayer G Reis; Albert I Ko; Daniel M Weinberger; Guilherme Ribeiro; Joice N Reis
Journal:  Vaccine       Date:  2015-12-29       Impact factor: 3.641

Review 3.  Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance.

Authors:  Joon Young Song; Moon H Nahm; M Allen Moseley
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

4.  Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands.

Authors:  Marloes Vissers; Alienke J Wijmenga-Monsuur; Mirjam J Knol; Paul Badoux; Marlies A van Houten; Arie van der Ende; Elisabeth A M Sanders; Nynke Y Rots
Journal:  PLoS One       Date:  2018-03-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.